Skip to main content

Liposomal doxorubicin

Details of the Drug
Generic Name:
Liposomal doxorubicin
Lip-SOH-mal dok-soh-ROO-bi-sin
Drug Type:
Antitumor antibiotic
How the Drug is Given:

Intravenously (IV)

Liposomal doxorubicin

Indications and Usage

Liposomal doxorubicin is FDA approved for use in combination with bortezomib to treat patients with myeloma who have not previously received bortezomib and have received at least one prior therapy. See the FDA announcement about drug shortage of Doxil.

Side effects needing medical attention

Loss of appetite (or weight loss); nausea; vomiting; stomach pain; diarrhea; constipation; unusual tiredness or weakness; dizziness; hair loss; nosebleed; red or orange discoloration of urine; sores in the mouth and throat; tingling, burning, redness, swelling, peeling or flaking, blisters, or sores on the palms of the hands or soles of the feet; pain, itching, redness, swelling, blisters, or sores in the place where the medication was injected. 

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.